MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
April 14, 2022
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted on the 14th of April an amount of €325 million by the Dutch National Growth Fund. Oncode Institute will lead the Oncode-PACT consortium and its operations. With this investment, the consortium will develop cancer drug candidates faster and bring them to patients sooner. As a partner in Oncode-PACT, MIMETAS will develop the next generation of patient-specific cancer organoid models that include immune cells, blood vessels, and other essential cell types to drive novel cancer drug discovery and development. Using these models, MIMETAS will screen compounds and targets using fully integrated, automatic phenotypic screening lines with AI data interpretation, bringing early validation and de-risking to the cancer drug development pipeline.
“Drug pipeline efficiency and scarcity of novel targets and disease mechanisms are critical challenges for cancer drug discovery and the pharmaceutical industry,” says Jos Joore, co-CEO of MIMETAS, “We are excited to deploy our groundbreaking 3D human cancer models in this outstanding consortium to, ultimately, offer cancer patients a better future.”
The goal of Oncode-PACT is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process itself. The project capitalizes on excellent cancer research in The Netherlands, one of the top three best-performing countries in biomedical sciences. In addition to MIMETAS, over forty leading parties from the oncology ecosystem participate in the consortium, including the Oncode Institute, pharmaceutical companies, SMEs, universities, hospitals, and social partners.
MIMETAS (Leiden, The Netherlands) is a global leader in disease modeling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables development and high-throughput screening of physiologically relevant disease models. The company offers its technology and know-how in therapy co-development projects, services, and off-the-shelf products. MIMETAS works with leading pharmaceutical and biotech companies worldwide to develop novel therapies against unsolved diseases. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown into a multinational company with operations in Asia, Europe, and the USA.
To learn more about MIMETAS' disease modeling capabilities and its OrganoPlate® platform, please visit www.mimetas.com
Oncode is an independent institute in the Netherlands dedicated to understanding cancer and translating research into practice. More than 800 excellent cancer researchers from 12 academic centers in the Netherlands come together in Oncode to collaborate in groundbreaking fundamental research. Along with performing vital basic research, Oncode is specialized in cooperating with third parties to guide scientists’ discoveries towards translational and clinical research and novel diagnostics, drugs and treatments. Oncode Institute was launched in 2017 and is funded by the Dutch Cancer Society, the Dutch Research Council (NWO) ZonMW, Health-Holland and three ministries: the Ministry of Economic Affairs and Climate Policy, the Ministry of Education, Culture and Science and the Ministry of Health, Welfare and Sports.
To learn more about Oncode and the Oncode-PACT initiative, please visit https://www.oncode.nl/Oncode-PACT
Jos Joore, CEO
+31 85 888 3161